2. Search Result
Search Result
Results for "

locomotor

" in MedChemExpress (MCE) Product Catalog:

105

Inhibitors & Agonists

14

Peptides

1

Inhibitory Antibodies

6

Natural
Products

3

Isotope-Labeled Compounds

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10895
    SB-334867
    Maximum Cited Publications
    10 Publications Verification

    SB 334867A

    		 Orexin Receptor (OX Receptor) Neurological Disease Endocrinology
    SB-334867 (SB 334867A) is an excellent,selective and blood-brain barrier permeable orexin-1 (OX1) receptor antagonist, shows selectivity over OX2 (pKb=7.4), 100-fold over 5-HT2B, 5-HT2C with pKi values of 5.4 and 5.3, respectively . SB-334867 reduces ethanol consumption and inhibits the acquisition of morphine-induced sensitization to locomotor activity in vivo .
    SB-334867
  • HY-W011689
    6PPD
    1 Publications Verification

    		 Reactive Oxygen Species (ROS) Others
    6PPD is a rubber antioxidant that scavenges ozone and forms nitro radicals. Exposure to 6PPD reduces the hatching rate, impairs spontaneous locomotor activity, shortens body length and causes malformations in zebrafish embryos. 6PPD also induces oxidative stress in zebrafish embryos .
    6PPD
  • HY-W013150
    Alpidem

    		GABA Receptor Neurological Disease
    Alpidem, an anxiolytic agent, is an orally active and brain-penetrant GABAA receptor ligand, binds to α1β2γ2 subunit-containing GABAA receptors (IC50 of 17 nM) over α5β2γ2 subunit-containing GABAA receptors (IC50 of >10 μM). Alpidem modulates calcium-induced mitochondrial permeability transition, induces glutathione depletion and hepatocyte necrosis, potentiates TNF-α toxicity, inhibits marble-burying and locomotor activity, enhances stressed rodent feeding behavior, and exerts anticonvulsant effects. Alpidem can be used for the research of anxiety, anxiety disorders, and convulsions .
    Alpidem
  • HY-10895A
    SB-334867 free base
    Maximum Cited Publications
    10 Publications Verification

    SB334867A free base

    		 Orexin Receptor (OX Receptor) Neurological Disease Endocrinology
    SB-334867 free base (SB334867A free base) is an excellent, selective and blood–brain barrier permeable orexin-1 (OX1) receptor antagonist, shows selectivity over OX2 (pKb=7.4), 100-fold over 5-HT2B, 5-HT2C with pKi values of 5.4 and 5.3, respectively . SB-334867 reduces ethanol consumption and inhibits the acquisition of morphine-induced sensitization to locomotor activity in vivo .
    SB-334867 free base
  • HY-15451
    MDA 19
    2 Publications Verification

    BZO-HEXOXIZID

    		 Cannabinoid Receptor Neurological Disease
    MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a Ki of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity .
    MDA 19
  • HY-B1002
    Oxolinic acid
    3 Publications Verification

    		 Bacterial Antibiotic DNA/RNA Synthesis Infection
    Oxolinic acid is an antibiotic against both Gram-negative and Gram-positive bacteria. Oxolinic acid can be used for the research of acute and chronic urinary tract infections. Oxolinic acid is a DNA/RNA synthesis inhibitor. Oxolinic acid acts a dopamine uptake inhibitor and stimulants locomotor effect in mice .
    Oxolinic acid
  • HY-117771
    DO34
    5 Publications Verification

    		 DAGL Neurological Disease Metabolic Disease
    DO34 is a selective DAGL inhibitor, with an IC50 of 6 nM for DAGLα conversion of SAG to 2-AG. DO34 blocks de novo 2-AG synthesis, and suppresses tonic CB1 receptor activation. DO34 blocks depolarization-induced suppression of excitation and inhibition in the cerebellum and hippocampus. DO34 regulates feeding behavior and locomotor activity in mice. DO34 abolishes AM251-mediated enhancement of parallel fiber-evoked excitatory postsynaptic currents in cerebellar slices from MAGL global knockout mice. DO34 can be used for the research of energy balance disorder and neuroinflammation .
    DO34
  • HY-175188
    MT-110

    BPN-0027490

    		 Myosin Neurological Disease
    MT-110 (BPN-0027490) is a non-muscle myosin NMIIB-selective inhibitor with high brain penetration and favorable safety profile. MT-110 specifically disrupts NMIIB-dependent actin dynamics in dendritic spines, while it exerts no significant adverse effects on cardiac myosin II and cardiac functions (such as cardiac output and heart rate) at tested concentrations. A single administration of MT-110 produces long-lasting (sustained for several weeks) blockade of methamphetamine motivation associated with environmental cues. MT-110 exhibits extremely high specificity, with no interference with cocaine motivation, hippocampus-dependent memory, fear memory, or locomotor and anxiety-like behaviors. MT-110 serves as a valuable tool compound for investigating the mechanisms of methamphetamine use disorder .
    MT-110
  • HY-A0277
    Cyproconazole

    		Environmental Pollutants Fungal Others
    Cyproconazole is a triazole fungicide used to protect crops, fruits and vegetables against a wide range of fungal pathogens. Cyproconazole can cause hepatocellular adenomas and carcinomas in CD-1 mice. Cyproconazole also exhibits low toxicity to zebrafish embryos and affects locomotor activity .
    Cyproconazole
  • HY-103505
    CL 218872

    		GABA Receptor Neurological Disease
    CL 218872 is an orally active and selective ligand for the benzodiazepine receptor subtype BZ1. CL 218872 exhibits anxiolytic, sedative and anticonvulsant activities. CL 218872 can be used in researches of anxiety related disorders and epilepsy .
    CL 218872
  • HY-12707
    Piribedil
    1 Publications Verification

    		 Dopamine Receptor Adrenergic Receptor Histone Methyltransferase Neurological Disease Endocrinology Cancer
    Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers .
    Piribedil
  • HY-113357
    m-Coumaric acid

    		Endogenous Metabolite Neurological Disease Metabolic Disease Inflammation/Immunology
    m-Coumaric acid is a polyphenol metabolite from caffeic acid, formed by the gut microflora and the amount in human biofluids is diet-dependant. m-Coumaric acid is a BBB-penetrant metabolite of chlorogenic acid. m-Coumaric acid stimulates the cerebral nerves in vitro. m-Coumaric acid can evoke neurite outgrowth in hippocampal neuronal cells. m-Coumaric acid can promote neuronal differentiation. m-Coumaric acid increases spontaneous locomotor activity in mice by acting on the central nervous system. m-Coumaric acid inhibits the oxidation of L-dopa by epidermis tyrosinase. m-Coumaric acid attenuates non-catalytic protein glycosylation in retinas of diabetic rats .
    m-Coumaric acid
  • HY-171844
    CX1739

    		iGluR Neurological Disease Inflammation/Immunology
    CX1739 is an orally active, blood-brain barrier permeable, low-efficacy AMPA-glutamate receptor (AMPAR) potentiator. CX1739 enhances excitatory neurotransmission by potentiating glutamate-induced excitatory currents and promoting in vivo long-term potentiation. CX1739 eliminates amphetamine-induced locomotor activity, reverses opioid-, pentobarbital- and ethanol-induced respiratory depression, and exerts pro-cognitive effects in animals. CX1739 impairs motor function recovery and increases the risk of post-injury complications. CX1739 can be used in research related to attention-deficit/hyperactivity disorder, dementia, respiratory depression and spinal cord injury .
    CX1739
  • HY-172550
    MS7710

    		HCN Channel Neurological Disease
    MS7710 is a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel inhibitor with blood-brain barrier permeability and an excellent brain/plasma concentration ratio. MS7710 inhibits HCN channel-mediated Ih current, and reduces the firing frequency and burst activity of dopaminergic neurons in the ventral tegmental area. MS7710 ameliorates chronic social defeat stress-induced deficits in social interaction and impairments in reward-related cognitive flexibility in mice. MS7710 exerts only limited effects on ventral tegmental area dopaminergic neuron activity, social interaction, exploratory behavior, locomotor activity or sucrose preference in control mice. MS7710 is applicable to the research of major depressive disorder .
    MS7710
  • HY-16361A
    Omigapil maleate

    CGP3466B; CGP3446 maleate; TCH346 maleate

    		 Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology
    Omigapil maleate (CGP3466B), an orally active GAPDH nitrosylation inhibitor, abrogates Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil maleate has the potential for the research of Alzheimer's disease. Omigapil maleate is a apoptosis inhibitor. Omigapil maleate can be used for the research of congenital muscular dystrophy (CMD). Omigapil maleate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups .
    Omigapil maleate
  • HY-103565
    AMN082
    1 Publications Verification

    		 mGluR Neurological Disease
    AMN082, a selective, orally active, and brain penetrant mGluR7 agonist, directly activates receptor signaling via an allosteric site in the transmembrane domain. AMN082 potently inhibits cAMP accumulation and stimulates GTPγS binding (EC50 values, 64-290 nM) at transfected mammalian cells expressing mGluR7. AMN082 shows selectivity over other mGluR subtypes and selected ionotropic glutamate receptors. Antidepressant effects .
    AMN082
  • HY-168773
    (R)-AS-1

    		EAAT Neurological Disease
    (R)-AS-1 is a selective positive allosteric modulator of the excitatory amino acid transporter 2 (EAAT2), with an EC50 of 11 nM. (R)-AS-1 (at doses of 60 and 90 mg/kg) increases spontaneous locomotor activity in mice. Additionally, it demonstrates anticonvulsant activity in mouse models of seizures induced by maximal electroshock (MES), pentylenetetrazole (PTZ), or electrical stimuli (32 or 44 mA), with ED50s of 66.3, 36.3, 15.6, and 41.6 mg/kg, respectively. (R)-AS-1 can be used in neurological disease research .
    (R)-AS-1
  • HY-118301
    ADX71441

    		GABA Receptor 5-HT Receptor Neurological Disease
    ADX71441 is an orally active, blood-brain barrier penetrant positive allosteric modulator of GABAB receptor. ADX71441 potentiates the activity of endogenous GABA at GABAB receptor, with an EC50 of 96 nM. ADX71441 functionally inhibits adenosine transporters and 5-HT2B receptor. ADX71441 produces anxiolytic-like, analgesic, muscle relaxant, hypothermic and overactive bladder inhibitory effects, reduces acute locomotor activity levels, decreases voluntary intake of alcohol and saccharin, attenuates stress-induced neuronal activation, and exhibits anti-hyperalgesic activity .
    ADX71441
  • HY-139178
    KVA-D-88

    		Phosphodiesterase (PDE) Neurological Disease
    KVA-D-88 is a blood-brain barrier-permeable PDE4 inhibitor with IC50 values of 140 and 880 nM for PDE4B and PDE4D, respectively. KVA-D-88 induces cAMP accumulation and inhibits neuroactive substance-mediated hyperlocomotion, locomotor sensitization. KVA-D-88 can be used for the research of drug addiction .
    KVA-D-88
  • HY-121870
    Dimethocaine

    Larocaine

    		 Drug Derivative Cytochrome P450 Neurological Disease
    Dimethocaine (Larocaine) is a cocaine derivative and ester-type local anesthetic. Dimethocaine is metabolized by hP450 1A2, 2C19, 2D6, and 3A4 in vitro. Dimethocaine exhibits locomotor-promoting, reinforcing, and anxiogenic effects .
    Dimethocaine
  • HY-136569
    DSR-141562

    		Phosphodiesterase (PDE) Neurological Disease
    DSR-141562 is a novel, orally active, and selective brain-penetrant phosphodiesterase 1 (PDE1) inhibitor. DSR-141562 shows preferential selectivity for human PDE1B with an IC50 of 43.9 nM, and the IC50 values for human PDE1A and 1C are 97.6 and 431.8 nM, respectively. DSR-141562 can be used for the study of positive symptoms, negative symptoms and cognitive impairments associated with schizophrenia .
    DSR-141562
  • HY-102062A
    Nω-Propyl-L-arginine hydrochloride
    1 Publications Verification

    N-omega-Propyl-L-arginine hydrochloride

    		 NO Synthase Neurological Disease
    Nω-Propyl-L-arginine (N-omega-Propyl-L-arginine) hydrochloride is a potent, competitive, and highly selective inhibitor of neuronal nitric oxide synthase (nNOS), with a Ki of 57 nM. Nω-Propyl-L-arginine hydrochloride displays a 149-fold selectivity for nNOS over endothelial NOS (eNOS) .
    Nω-Propyl-L-arginine hydrochloride
  • HY-102062
    Nω-Propyl-L-arginine
    1 Publications Verification

    N-omega-Propyl-L-arginine

    		 NO Synthase Neurological Disease
    Nω-Propyl-L-arginine (N-omega-Propyl-L-arginine) is a potent, competitive, and highly selective inhibitor of neuronal nitric oxide synthase (nNOS), with a Ki of 57 nM. Nω-Propyl-L-arginine displays a 149-fold selectivity for nNOS over endothelial NOS (eNOS) .
    Nω-Propyl-L-arginine
  • HY-P99959
    Unasnemab

    MT-3921; rH116A3

    		 TGF-β Receptor Neurological Disease
    Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments .
    Unasnemab
  • HY-P1329A
    CTOP TFA
    1 Publications Verification

    		 Opioid Receptor Neurological Disease
    CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity .
    CTOP TFA
  • HY-103429
    Quinelorane dihydrochloride

    LY163502

    		 Dopamine Receptor Neurological Disease
    Quinelorane dihydrochloride (LY163502) is a potent dopamine D3/D2 receptor agonist. Quinelorane has the potential for neurological and psychiatric disorders research .
    Quinelorane dihydrochloride
  • HY-108510
    Rimcazole dihydrochloride

    BW 234U dihydrochloride

    		 Sigma Receptor Dopamine Receptor Neurological Disease Cancer
    Rimcazole (BW 234U) dihydrochloride is a carbazole derivative that acts in part as a sigma (σ) receptor antagonist. Rimcazole dihydrochloride also binds with moderate affinity to the dopamine transporter and inhibit dopamine uptake. Rimcazole dihydrochloride can reduce locomotor activity and sensitization. Rimcazole dihydrochloride also can be used for the research of cancer .
    Rimcazole dihydrochloride
  • HY-W015616
    Benzylacetone

    4-Penylbutan-2-one

    		 Environmental Pollutants Tyrosinase Infection Metabolic Disease
    Benzylacetone (4-Penylbutan-2-one) is an aromatic compound. Benzylacetone is a mushroom tyrosinase inhibitor with an IC50 of 2.8 mM, a Ki of 1.25 mM for monophenolase and an IC50 of 0.6 mM, a Ki of 0.39 mM for diphenolase. Benzylacetone inhibits free mushroom tyrosinase and enzyme-substrate complex. Benzylacetone acts as an appetite enhancer via olfactory stimulation, reduces spontaneous locomotor activity, induces weight gain. Benzylacetone exhibits repellent, fumigant, and contact toxicity against Tribolium castaneum adults .
    Benzylacetone
  • HY-101102
    7-Hydroxy-DPAT hydrobromide

    		Dopamine Receptor Neurological Disease
    7-Hydroxy-DPAT hydrobromide is a selective D3 dopamine receptor agonist, exhibiting significant pharmacological activity in modulating locomotor behavior and dopamine metabolism within the brain.
    7-Hydroxy-DPAT hydrobromide
  • HY-145454
    (R)-Preclamol

    (+)-3-PPP

    		 Dopamine Receptor Neurological Disease
    (R)-Preclamol is a dopamine (DA) agonist with autoreceptor as well as postsynaptic receptor stimulatory properties. (R)-Preclamol inhibits the locomotor activity of mice and rats in low doses .
    (R)-Preclamol
  • HY-P1329
    CTOP

    		Opioid Receptor Neurological Disease
    CTOP is a potent and highly selective μ-opioid receptor antagonist. CTOP antagonizes the acute morphine-induced analgesic effect and hypermotility. CTOP enhances extracellular dopamine levels in the nucleus accumbens. CTOP dose-dependently enhances locomotor activity .
    CTOP
  • HY-P10405A
    TAT-D1 peptide acetate

    		Dopamine Receptor Neurological Disease
    TAT-D1 peptide acetate is a dopamine D1-D2 receptor heterodimer inhibitor. TAT-D1 peptide acetate disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization. TAT-D1 peptide acetate produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety, and inhibits c-fos expression in the nucleus accumbens of rats. TAT-D1 peptide acetate can be used in the research of psychostimulant addiction, depression and anxiety disorders .
    TAT-D1 peptide acetate
  • HY-A0277R
    Cyproconazole (Standard)

    		Reference Standards Fungal Others
    Cyproconazole (Standard) is the analytical standard of Cyproconazole. This product is intended for research and analytical applications. Cyproconazole is a triazole fungicide used to protect crops, fruits and vegetables against a wide range of fungal pathogens. Cyproconazole can cause hepatocellular adenomas and carcinomas in CD-1 mice. Cyproconazole also exhibits low toxicity to zebrafish embryos and affects locomotor activity .
    Cyproconazole (Standard)
  • HY-B1002R
    Oxolinic acid (Standard)

    		Reference Standards Bacterial Antibiotic DNA/RNA Synthesis Infection
    Oxolinic acid (Standard) is the analytical standard of Oxolinic acid. This product is intended for research and analytical applications. Oxolinic acid is an antibiotic against both Gram-negative and Gram-positive bacteria. Oxolinic acid can be used for the research of acute and chronic urinary tract infections. Oxolinic acid is a DNA/RNA synthesis inhibitor. Oxolinic acid acts a dopamine uptake inhibitor and stimulants locomotor effect in mice .
    Oxolinic acid (Standard)
  • HY-172587
    CB1R Allosteric modulator 5

    		Cannabinoid Receptor Neurological Disease
    CB1R Allosteric modulator 5 (compound 3) is a selective, and blood-brain barrier (BBB) permeable Cannabinoid receptor type 1 allosteric modulator with a pIC50 of 6.89. CB1R Allosteric modulator 5 attenuates both cocaine-seeking behavior specific to cue-induced reinstatement and cocaine-induced behavioral sensitization without altering locomotor activity .
    CB1R Allosteric modulator 5
  • HY-113357R
    m-Coumaric acid (Standard)

    		Reference Standards Endogenous Metabolite Neurological Disease Inflammation/Immunology
    m-Coumaric acid (Standard) is the analytical standard of m-Coumaric acid. This product is intended for research and analytical applications. m-Coumaric acid is a polyphenol metabolite from caffeic acid, formed by the gut microflora and the amount in human biofluids is diet-dependant. m-Coumaric acid is a BBB-penetrant metabolite of chlorogenic acid. m-Coumaric acid stimulates the cerebral nerves in vitro. m-Coumaric acid can evoke neurite outgrowth in hippocampal neuronal cells. m-Coumaric acid can promote neuronal differentiation. m-Coumaric acid increases spontaneous locomotor activity in mice by acting on the central nervous system. m-Coumaric acid inhibits the oxidation of L-dopa by epidermis tyrosinase. m-Coumaric acid attenuates non-catalytic protein glycosylation in retinas of diabetic rats .
    m-Coumaric acid (Standard)
  • HY-160718
    Adrogolide

    ABT-431; DAS-431

    		 Dopamine Receptor Neurological Disease
    Adrogolide is an A-86929 (HY-171472) prodrug and dopamine D1 receptor agonist. Adrogolide is converted rapidly in plasma to A-86929. Adrogolide improves behavioral disability and locomotor activity scores. Adrogolide can also attenuate the ability of Cocaine to induce Cocaine-seeking behavior. Adrogolide can be used in the research of Parkinson's disease .
    Adrogolide
  • HY-123889
    VK4-116

    		Dopamine Receptor Neurological Disease
    VK4-116 (Compound 19) is a selective Dopamine D3 receptor (D3R) antagonist with a Ki of 6.84 nM.VK4-116 significantly inhibits Oxycodone-induced hyperlocomotion and locomotor sensitization in mouse models. VK4-116 with pretreatment also inhibits the acquisition of Oxycodone-induced conditioned place preference (CPP) in rat models .
    VK4-116
  • HY-P10405
    TAT-D1 peptide

    		Dopamine Receptor Neurological Disease
    TAT-D1 peptide is a dopamine D1-D2 receptor heterodimer inhibitor. TAT-D1 peptide disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization. TAT-D1 peptide produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety, and inhibits c-fos expression in the nucleus accumbens of rats. TAT-D1 peptide can be used in the research of psychostimulant addiction, depression and anxiety disorders .
    TAT-D1 peptide
  • HY-133533
    O-2050

    		Cannabinoid Receptor Neurological Disease
    O-2050 is a high affinity cannabinoid CB1 receptor antagonist with a Ki of 2.5 nM. O-2050 inhibits cannabinoid CB2 receptor (Ki=0.2 nM). O-2050 can cause locomotor stimulation in mice .
    O-2050
  • HY-107055
    RTI 336

    		Dopamine Transporter Neurological Disease
    RTI 336 is a phenyltropane analog, as well as a potent and selective dopamine transporter (DAT) inhibitor. RTI 336 inhibits addictive agent induced locomotor activity and self-administration in Lewis rats. RTI 336 exhibits inhibitory effects depending on inherent NAc DAT levels .
    RTI 336
  • HY-101357
    CP 93129

    		5-HT Receptor Neurological Disease
    CP 93129 is a potent and selective 5-HT1B agonist. CP 93129 has the potential for the research of Parkinson's disease .
    CP 93129
  • HY-134015
    7-Hydroxy-DPAT

    7-OH-DPAT

    		 Dopamine Receptor Neurological Disease
    7-Hydroxy-DPAT (7-OH-DPAT) is a selective D3 dopamine receptor agonist. 7-Hydroxy-DPAT exhibits significant pharmacological activity in modulating locomotor behavior and dopamine metabolism within the brain. 7-Hydroxy-DPAT can be used for the research of neurological disease .
    7-Hydroxy-DPAT
  • HY-B1002S
    Oxolinic acid-d5

    		Isotope-Labeled Compounds Bacterial Antibiotic DNA/RNA Synthesis Infection
    Oxolinic acid-d5 is the deuterium labeled Oxolinic acid. Oxolinic acid is an antibiotic against both Gram-negative and Gram-positive bacteria. Oxolinic acid can be used for the research of acute and chronic urinary tract infections. Oxolinic acid is a DNA/RNA synthesis inhibitor. Oxolinic acid acts a dopamine uptake inhibitor and stimulants locomotor effect in mice .
    Oxolinic acid-d5
  • HY-107751
    BW373U86

    SNC86

    		 Opioid Receptor Neurological Disease
    BW373U86 (SNC86) is a δ-opioid receptor agonist with an IC50 of 1.49 nM. BW373U86 shows antidepressant-like effects .
    BW373U86
  • HY-103565A
    AMN082 free base
    1 Publications Verification

    		 mGluR Neurological Disease
    AMN082 free base, a selective, orally active, and brain penetrant mGluR7 agonist, directly activates receptor signaling via an allosteric site in the transmembrane domain. AMN082 free base potently inhibits cAMP accumulation and stimulates GTPγS binding (EC50 values, 64-290 nM) at transfected mammalian cells expressing mGluR7. AMN082 free base shows selectivity over other mGluR subtypes and selected ionotropic glutamate receptors. Antidepressant effects .
    AMN082 free base
  • HY-A0139
    Thiothixene

    NSC 108165; Navan; Navane

    		 Sigma Receptor mAChR Histamine Receptor Dopamine Receptor Adrenergic Receptor Others
    Thiothixene is a typical antipsychotic. It selectively binds to dopamine D2 over D1, D3, and D4 receptors (Kis=0.417, 338, 186.2, and 363.1 nM, respectively). Thiothixene also binds to various serotonin (5-HT), histamine H1, α1- and α2-adrenergic, muscarinic acetylcholine, and sigma receptors (Kis=15-5,754 nM) as well as the dopamine, norepinephrine, and serotonin transporters (Kis=3.16-30 μM). In vivo, thiothixene reduces spontaneous and amphetamine-induced locomotor activity in rats. It enhances latent inhibition, as measured by a decreased lick latency in response to light and foot shock stimuli, which is a measure of selective attention in rats.3 Thiothixene also increases competitive behavior in submissive mice, indicating antidepressant-like behavior.
    Thiothixene
  • HY-123440
    S3608

    		Dopamine Receptor Neurological Disease
    S3608 is an atypical dopamine agonist. S3608 dose dependently increase locomotor activity (LA) in rats .
    S3608
  • HY-121775
    PF-00217830

    		Dopamine Receptor Neurological Disease
    F-00217830 is an agonist ofDopamine D2 receptor. PF-00217830 inhibits of spontaneous locomotor activity and 2,5-dimethoxy-4-iodoamphetamine-induced head twitches in rats .
    PF-00217830
  • HY-168365
    (±)-Pellotine hydrochloride

    		Drug Isomer Neurological Disease
    (±)-Pellotine hydrochloride (Compound 2) is an alkaloid, which is found in L. diffusa and L. fricii. (±)-Pellotine hydrochloride decreases locomotor activity and the amount of rapid eye movement (REM) sleep in mice .
    (±)-Pellotine hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: